在广东汕头，一家拥有130余年历史的中药企业正焕发新生。 广东万年青（000789）制药股份有限公司（粤万年青（301111））董事长、总裁欧先涛在接受中国证券 报记者采访时介绍，近年来，公司收购了上游饮片企业，进入健康食品领域，打造提供一站式健康管理 的万年青国际医疗港，不断完善全产业链布局，从传统药企升级为覆盖"医药+健康食品+医疗"的综合 性大健康集团。粤万年青正以"中华老字号"的深厚积淀为基，以科技创新为翼，在传承与创新中书写中 医药现代化的新篇章。 传承非遗技艺 2024年，"万年青"被商务部认定为"中华老字号"，这一认证标志着粤万年青跨越三个多世纪的技艺传承 与品质坚守获得认可，成为企业在中医药市场中的金字招牌。 欧先涛介绍，粤万年青目前拥有101个药品批文，32个原研首创产品，10个独家品种，4个独家剂型，16 个国家基药目录产品，38个产品列入国家医保目录。重点产品包括参芪降糖片、益心丸、消炎利胆片 等。万年青固精补肾丸制作技艺被认定为汕头市第八批市级非物质文化遗产代表性项目，公司也被认定 为非物质文化遗产代表性项目保护单位。 粤万年青也致力于实现中药生产的现代化和智能化。公司通过技术创新实现 ...

● 本报记者 万宇 在广东汕头，一家拥有130余年历史的中药企业正焕发新生。 公司药品线下覆盖3万家药店和2000多家医疗终端，销售网络覆盖全国，在各大中城市都有自己的销售 队伍，产品覆盖了医院、诊所、卫生站、药店等各类终端，并积极拓展天猫、抖音、小程序等线上销售 渠道，覆盖更广泛的消费者。 "'中华老字号'的认定，为粤万年青确立了中医药现代化转型的时代坐标。我们正以这一殊荣为新起 点，构建传统与现代深度融合的创新模式。一方面，将公司134年的中医药发展历史和非遗制药技艺转 化为'可体验的文化IP'，弘扬中医药文化，传播中医药知识；另一方面，通过数字化升级让非遗炮制技 艺标准化、可传承，借助药食同源创新让中医药融入日常健康管理，并融合AI、大数据等新科技，来 确保我们的百年品质始终如一。"欧先涛说。 创新驱动发展 中医药的现代化离不开科技创新的赋能。欧先涛介绍，近年来，粤万年青以"古法传承+智能制造"为发 展理念，在保留传统炮制工艺与经典配方核心的基础上，全面推进生产现代化与智能化升级，构建 起"研发－生产－质控"全链条的技术优势。 在生产环节，一系列创新技术的应用让传统中药生产焕发新生。真空低温履带技术、超 ...

Group 1: Company Performance - In 2024, the company achieved operating revenue of 27,863.88 million yuan, a decrease of 1,375.83 million yuan, representing a year-on-year decline of 4.71% [5] - The net profit attributable to shareholders was 416.27 million yuan, down 2,933.90 million yuan, a decline of 87.57% year-on-year [5] - The decrease in profit was primarily due to strategic investments in new business segments, which increased operational costs without generating significant revenue [5] Group 2: Digital Marketing and Sales Strategy - The company is enhancing digital marketing through two main approaches: upgrading pharmaceutical innovation and smart manufacturing, and developing a digital retail platform [2] - The company plans to leverage new retail marketing experiences from its subsidiary to boost online sales of OTC drugs via platforms like Douyin [6] - A dual-channel approach is being adopted for medical services, combining online and offline methods to improve service efficiency and product sales [6] Group 3: New Business Development - The company has established the Wan Nian Qing International Medical Port, a comprehensive medical complex in eastern Guangdong, collaborating with leading medical brands [4] - The new business segment is still in the cultivation phase and has not yet generated profit [4] - The company is focusing on integrating online and offline resources to create a seamless service experience [4] Group 4: Market Trends and Competitive Position - The company is responding to the growing demand for traditional Chinese medicine and health products, particularly in the context of an aging population and increasing health awareness [10] - The company aims to differentiate itself by leveraging its long-standing brand heritage and integrating various health services [10] - The overall pharmaceutical industry saw a slight decline in revenue and profit, with the company’s performance aligning with industry trends [10] Group 5: Regulatory and Policy Impact - The company’s product, Can Qi Jiang Tang Pian, has been selected for national centralized procurement, which may reduce its price by approximately 30% but is expected to expand its market reach [9] - The company is committed to complying with national policies aimed at enhancing the quality of traditional Chinese medicine [11]

Core Insights - The article highlights the successful conclusion of the "Compliance New Journey, Building the Future" private meeting hosted by Yue Wannianqing and Guotou Securities, emphasizing the company's commitment to innovation and its leading position in the traditional Chinese medicine sector [1] Company Overview - Yue Wannianqing, with over 130 years of history, originated from the Shantou Pharmaceutical Factory and has established a strong reputation in drug research, production, and sales [2] - The company adheres to the principles of "innovation, excellence, and quality first," and has developed specialized brands in areas such as gallbladder health, diabetes management, and kidney support [2] - The "Wannianqing" brand was recognized as a "Chinese Time-Honored Brand" in February 2024, reflecting its brand value in the traditional Chinese medicine industry [2] Market Trends - The demand for traditional Chinese medicine (TCM) has been increasing, driven by factors such as an aging population, changes in dietary structure, and environmental pollution [2] - There is a notable shift in disease patterns from infectious to chronic non-communicable diseases, with rising incidences of cardiovascular, respiratory, and endocrine diseases, where TCM shows advantages in treatment [2] Product Development - Yue Wannianqing has developed a diverse product portfolio, including 101 products with national drug approval, covering various forms such as tablets, capsules, and injections [3] - The company has 32 original innovative products, 10 exclusive varieties, and 4 unique dosage forms, with 38 products included in the national medical insurance directory [3] - The company has increased its R&D investment, focusing on product innovation and improvement, and its product "Shenqi Jiangtang Pian" has been selected for national centralized procurement [3][4] Strategic Expansion - To explore new growth opportunities, Yue Wannianqing has extended its business into the health industry chain, acquiring 85% of Guangdong Tongren Pharmaceutical Co., now known as Guangdong Wannianqing Pharmaceutical Co., focusing on the production and trade of Chinese medicinal materials [5] - The company has also invested in the establishment of the Wannianqing International Medical Port, a comprehensive healthcare complex in Shantou, which integrates various medical services and aims to meet diverse healthcare needs in the region [6]